Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on January 19, 2021. The filing details the execution of new employment agreements for the Chief Executive Officer and Chief Financial Officer, as well as compensation adjustments for non-employee directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive and director compensation arrangements.
Material Changes and Compensation Details
- CEO Agreement: Raymond Joseph Tesi's agreement effective January 1, 2021, includes a base salary of $455,000 per annum and a target annual discretionary bonus of 50% of base salary. He received an option to purchase 59,337 shares at $24.82 per share, vesting 25% on January 18, 2022, with the remainder vesting monthly over three years. Severance for involuntary termination is 18 months of base salary.
- CFO Agreement: David J. Moss's agreement effective January 1, 2021, includes a base salary of $359,000 per annum and a target annual discretionary bonus of 40% of base salary. He received an option to purchase 59,337 shares at $24.82 per share with identical vesting terms to the CEO. Severance for involuntary termination is 18 months of base salary.
- Director Compensation: The Board approved $20,000 per annum cash compensation for each non-employee director (excluding David Szymkowski). Additionally, five non-employee directors were granted options to purchase an aggregate of 79,875 shares (15,975 shares each) at $24.82 per share, vesting quarterly over three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that the full employment agreements and option agreements will be filed as exhibits to the Annual Report on Form 10-K for the year ended December 31, 2020.
Investor Verification Checklist
- Verify the full text of the employment agreements for Dr. Tesi and Mr. Moss in the upcoming Form 10-K.
- Confirm the specific vesting schedules and exercise conditions in the option agreements filed as exhibits.
- Review the definition of "Involuntary Termination" in the agreements to understand severance triggers.
- Check the Form 10-K for the total number of shares outstanding and the impact of these new option grants on dilution.